This finding is further supported by a French nationwide cohort study [17], which demonstrated a heightened lymphoma risk in IBD patients receiving thiopurine monotherapy (HR 2.6), anti-TNF monotherapy (HR 2.4), or combination therapy (HR 6.1) compared to unexposed IBD patients. This evidence concerns the gene TNF and lymphoma.